GenTel Appoints Burke to its Scientific Advisory Board ( MADISON Wis. October 17 2003. GenTel...)

GenTel Appoints Burke to its Scientific Advisory Board

MADISON, Wis. October 17, 2003. GenTel BioSurfaces, Inc., a privately held UWMadison biotechnology spin-off, announced today that it has appointed Thomas J. Burke, Ph.D., to its Scientific Advisory Board.

"Tom's extensive scientific experience, as well as his demonstrated expertise in grant writing, intellectual property management, and new product development make him ideally suited to ......

Full article >>>

Source:wistechnology.com By WTN News 10/16/03

Page: 1 2
Related biology technology :

1. GenTel acquires GlaxoSmithKline chip platform
2. New angel capital centered on GenTel agreement with big pharma
3. GenTel licenses next generation cancer research
4. GenTel to distribute cancer research tool
5. GenTel gets federal grant to develop allergy test
6. Madisons GenTel partners with Taiwan firm
7. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
8. GenTel BioSurfaces launches new assay platform
9. GenTel will sell Dutch firms biomolecule labeling technology
10. Bone Care, GenTel, MyWeather
11. GenTel receives $250,000 state loan

Post Your Comments:

(Date:5/21/2013)... 2013 MacroGenics, Inc. today announced that an ... an Fc-modified chimeric monoclonal antibody (MAb), in patients ... will be presented at the 2013 Annual Meeting ... the Developmental Therapeutics - Immunotherapy Oral Abstract Session ... PM. The presentation will describe the results of ...

(Date:5/21/2013)... -- Personal Genome Diagnostics Inc. (PGDx), today announced that ... in genomic analysis of defined cancer subtypes to ... Medicines. PGDx is an innovator in conducting patient-specific ... and Blueprint Medicines is an expert in developing ... patient population. "This collaboration brings together ...

(Date:5/21/2013)... May 21, 2013 Revolutionary Science, the ... colony counter, announced today that they have expanded their ... , the IncuCount, IntelliCount, InCount and ImpressCount. These ... are especially useful in food microbiology and pharmaceutical manufacturing. ... updated look. A bright white enclosure with jet ...

(Date:5/21/2013)... Inflamax scientists worked closely with internationally ... the study, which will provide critical insight into ... in the study of allergy treatments, the Environmental ... models. Although both the models are well recognized ... direct comparison between the allergic responses evoked by ...

Breaking Biology Technology:MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2 MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3 Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2 Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3 Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2 Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2

[0] MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer [0] Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets [0] Revolutionary Science Announces New Automatic and Manual Colony Counting Products [0] Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation.

... trial indicate statistically significant reduction in recurrences ... ... JAMAICA PLAIN, Mass., Nov. 3 /PRNewswire-FirstCall/,-- Medarex, Inc. (Nasdaq: MEDX ... Medical School (UMMS) today,announced that a Phase 2 trial of an ...

... Cepheid (Nasdaq:,CPHD) today announced that it ... Stretton Scientific Limited, a privately held distributor ... in,Stretton, England. Stretton Scientific currently distributes Cepheid,s,SmartCycler(R) ... products, to,a broad group of medical customers ...

... financial guidance through second quarter of 2009 - ... - Conference ... BRANFORD, Conn., Nov. 3 CuraGen Corporation,(Nasdaq: CRGN ), today ... the three month period ended September 30, 2008, CuraGen,utilized $3.6 million ...

Cached Biology Technology:Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 2 Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 3 Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 4 Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 5 Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 6 Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific 2 Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific 3 CuraGen Reports Third Quarter 2008 Financial Results 2 CuraGen Reports Third Quarter 2008 Financial Results 3 CuraGen Reports Third Quarter 2008 Financial Results 4 CuraGen Reports Third Quarter 2008 Financial Results 5 CuraGen Reports Third Quarter 2008 Financial Results 6

Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific CuraGen Reports Third Quarter 2008 Financial Results

(Date:5/21/2013)... most deadly when they metastasize and spread tumors throughout ... becomes very difficult for doctors to locate and treat ... the University of Missouri have found a way to ... they may be in the body. Michael Lewis, an ... Veterinary Medicine, says being able to target secondary tumors ...

(Date:5/21/2013)... in pharmacies and health stores, phosphatidylserine is a ... soy. Proven to improve cognition and slow memory ... experiencing memory impairment. Now a team headed by ... Tel Aviv University,s Department of Human Molecular ... improves the functioning of genes involved in degenerative ...

(Date:5/21/2013)... in shape is an uphill battle? Try staying fit ... weightlessness withers muscle and bone. , That,s the challenge ... with a new three-year, $1.2 million grant from NASA. ... during multiyear exploratory missions. , "You could give astronauts ... can,t get them to stick to it, it isn,t ...

Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2 Common food supplement fights degenerative brain disorders 2 Fueling fitness on the final frontier 2

[0] MU researchers develop radioactive nanoparticles that target cancer cells [0] Common food supplement fights degenerative brain disorders [0] Fueling fitness on the final frontier

... birds often choose their mates based on fancy feathers. ... likely to follow their noses to the right mate. ... Harvard researcher Katherine McAuliffe, whose review of evidence for ... issue of The Quarterly Review of Biology . ...

... that belongs to the oldest living family of jawed vertebrates, ... discovery, published in the March 2009 issue of Genome ... evolved in early vertebrates over the last 450 million years ... vertebrate like the elephant shark had the potential for color ...

... a novel regulator of p53, an important protein that safeguards ... March 17, 2009 issue of the journal Genes & ... this microRNA keeps the level of p53 low to avoid ... damaged, the microRNA level is reduced to allow an increase ...

Cached Biology News:Female mammals follow their noses to the right mates 2 Elephant shark genome sequence leads to discovery of color perception in deep-sea fish 2 Regulatory molecule for tumor formation or suppression identified by Singapore, US researchers 2

Female mammals follow their noses to the right mates Elephant shark genome sequence leads to discovery of color perception in deep-sea fish Regulatory molecule for tumor formation or suppression identified by Singapore, US researchers

... 9 oligodeoxynucleotides are random ... at the 5' end ... Fluor dyes and they ... microarray spot morphology, hybridization ...

Mycoplasma tested...

The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...

... Our fastest automated perfusion system. For ... perfusion, physiology, biophysics, electrochemistry, or general ... with 1.5-4 millisecond accuracy Run ... Microprocessor-based for accuracy and flexibility ...

Biology Products:

Panomer 9 random oligodeoxynucleotide, Alexa Fluor 647 conjugate from Molecular Probes (Invitrogen)GIBCO Chicken Serum from Invitrogen Spheroplast Kit for Yeast from Invitrogen ValveLink8.2 Lee Valve 1.5-4ms Perfusion System from AutoMate Scientific, Inc